X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3) 3
adult (2) 2
aged (2) 2
ceritinib (2) 2
female (2) 2
humans (2) 2
kinases (2) 2
lymphomas (2) 2
male (2) 2
middle aged (2) 2
oncology (2) 2
resistance (2) 2
absorption (1) 1
acute lymphatic leukemia (1) 1
alectinib (1) 1
alk inhibitor (1) 1
anaplastic lymphoma kinase (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
ap24534 (1) 1
ap26113 (1) 1
asian continental ancestry group (1) 1
bioavailability (1) 1
bosutinib (1) 1
brain metastases (1) 1
brigatinib (1) 1
cancer (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - genetics (1) 1
cell lung-cancer (1) 1
chemotherapy (1) 1
chronic myeloid leukemia (1) 1
chronic myeloid-leukemia (1) 1
cml (1) 1
crizotinib-resistant (1) 1
dasatinib (1) 1
diet (1) 1
dose proportionality (1) 1
experience (1) 1
food (1) 1
food effect (1) 1
gene rearrangement (1) 1
genetic aspects (1) 1
genetic research (1) 1
healthy-subjects (1) 1
hematology (1) 1
hematology, oncology and palliative medicine (1) 1
hypertension (1) 1
imatinib (1) 1
imidazoles - administration & dosage (1) 1
imidazoles - adverse effects (1) 1
inhibitors (1) 1
japanese population (1) 1
leukemia (1) 1
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1) 1
leukopenia (1) 1
lung cancer (1) 1
lung cancer, non-small cell (1) 1
lung neoplasms - drug therapy (1) 1
lung neoplasms - genetics (1) 1
lymphatic leukemia (1) 1
mechanisms (1) 1
medical colleges (1) 1
medicine & public health (1) 1
metastasis (1) 1
mutations (1) 1
myeloid leukemia (1) 1
neutropenia (1) 1
non-small-cell lung cancer (1) 1
non–small-cell lung cancer (1) 1
non–small‐cell lung cancer (1) 1
oils & fats (1) 1
oncology, experimental (1) 1
organophosphorus compounds - adverse effects (1) 1
organophosphorus compounds - therapeutic use (1) 1
original manuscript (1) 1
patients (1) 1
ph plus all (1) 1
ph+all (1) 1
pharmaceutical industry (1) 1
pharmacokinetics (1) 1
pharmacology & pharmacy (1) 1
phase 1/2 (1) 1
philadelphia chromosome (1) 1
ponatinib (1) 1
potent (1) 1
protein kinase inhibitors - adverse effects (1) 1
protein kinase inhibitors - therapeutic use (1) 1
protein-tyrosine kinase (1) 1
pyridazines - administration & dosage (1) 1
pyridazines - adverse effects (1) 1
pyrimidines - adverse effects (1) 1
pyrimidines - therapeutic use (1) 1
quality (1) 1
receptor protein-tyrosine kinases - antagonists & inhibitors (1) 1
receptor protein-tyrosine kinases - genetics (1) 1
research (1) 1
research institutes (1) 1
safety (1) 1
studies (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1683 - 1696
Journal Article
International Journal of Hematology, ISSN 0925-5710, 9/2017, Volume 106, Issue 3, pp. 385 - 397
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 08/2019, Volume 8, Issue 6, pp. 734 - 741
Brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor, received accelerated approval in the United States for the treatment of patients with... 
brigatinib | Absorption | food effect | non–small‐cell lung cancer | anaplastic lymphoma kinase | non–small-cell lung cancer | MECHANISMS | ALK INHIBITOR | BIOAVAILABILITY | CELL LUNG-CANCER | AP26113 | POTENT | CERITINIB | RESISTANCE | PHARMACOLOGY & PHARMACY | non-small-cell lung cancer | FOOD | Index Medicus | Original Manuscript
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.